The U.S. Food and Drug Administration has granted approval for EntroGen’s CRCdx® RAS Mutation Detection Kit as a companion diagnostic for Vectibix®, a targeted therapy used in the treatment of colorectal cancer.
The U.S. Food and Drug Administration has granted approval for EntroGen’s CRCdx® RAS Mutation Detection Kit as a companion diagnostic for Vectibix®, a targeted therapy used in the treatment of colorectal cancer.